Protein Kinase G (PKG) is a critical mediator of nitric oxide signaling which regulates cardiovascular homeostasis. It has been shown that PKG-I knockout (Prkg1 -/-) mice exhibit impaired nitric oxide/cGMP-dependent vasorelaxation and systemic hypertension. However, it remains unknown whether PKG-I deficiency induces pulmonary hypertension. Here we characterize the hypertensive pulmonary phenotypes in Prkg1 -/-mice and delineate the underlying molecular basis. We observed significant increase in right ventricular systolic pressure in Prkg1 -/-mice in the absence of systemic hypertension and left heart dysfunction. We also observed marked muscularization of distal pulmonary vessels in Prkg1 -/-mice.
Introduction:
Pulmonary hypertension (PH) characterized by progressive increases in pulmonary vascular resistance and vascular remodeling causes right-sided heart failure and mortality without treatment 1, 2 . Increased pulmonary vascular tone and severe structural remodeling of distal pulmonary vasculature are primary determinants of increased pulmonary vascular resistance. As the molecular mechanisms responsible for pulmonary vascular remodeling and vasoconstriction remain elusive, there are limited options available for the prevention and treatment of progressive PH 3, 4 Protein kinase G (PKG), a serine/threonine kinase, plays an important role in the regulation of vascular smooth cell contractility . 5, 6 . Activation of soluble guanylyl cyclase by nitric oxide (NO) leads to increased synthesis of cGMP and activation of PKG. PKG activation results in vasorelaxation via several mechanisms including lowering of intracellular free Ca 2+ levels, and desensitization of the contractile apparatus to Ca 2+ 7, 8 . Two mammalian Prkg genes have been identified, encoding PKG-I and PKG-II 9 . PKG-I is the prevalent PKG isoform expressed in the cardiovascular system with greater level in smooth muscle cells whereas lower level in endothelial cells 10, 11 . The N-terminus (the first 90-100 residues) of PKG-I is encoded by two alternative exons generating two isoforms PKG-Iα and PKG-Iβ 9 . The enzyme is activated at submicromolar to micromolar concentrations of cGMP. PKG-I is composed of three functional domains: a N-terminal domain, a regulatory domain and a catalytic domain. The regulatory domain contains two cGMP-binding sites with high and low affinity. The catalytic domain contains the Mg-ATP-and peptide-binding pockets. Binding of cGMP to the regulatory domain releases the inhibition of the catalytic center by the N-terminal autoinhibitory/pseudosubstrate site and allows the phosphorylation of serine/threonine residues in target proteins 6, 12 . PKG-I phosphorylates Rho A at Ser 188 which inhibits its membrane association and thereby prevents activation of its downstream targets such as Rho kinase 13, 14 .
Rho kinase-mediated phosphorylation of human myosin phosphatase target subunit 1 at Threonine 696 (corresponding to Threonine 694 in mouse) inhibits smooth muscle myosin phosphatase activity and induces smooth muscle cell contraction 15
Prkg1
.
-/-mice exhibit impaired NO/cGMP-dependent vasorelaxation and systemic hypertension in their early life [16] [17] [18] [19] [20] . These mutant mice also exhibit decreased life span (50% of these mice die before 5 to 6 weeks of age) 17 , diminished ischemia-induced angiogenesis 21 , and disturbed platelet adhesion and activation 22 . Overexpression of PKG-I increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of NO/cGMP 23 whereas downregulation of PKG-I induces the change of smooth muscle cell phenotype from a contractile, differentiated to a synthetic, dedifferentiated state 24, 25 , an underlying feature of pulmonary vascular remodeling. Although PKG dysfunction has been indicated in the pathogenesis of PH, there is no genetic evidence demonstrating PKG-I deficiency induces PH. Here we report that deletion of Prkg1 induces vascular remodeling and vasoconstriction and thereby PH in mice.
Materials and Methods
Mice. All mice were bred and maintained in the University of Illinois at Chicago facility according to NIH guidelines. Approval for animal care and use in these experiments was granted by the Animal Care and Use Committee.
Primary cultures of mouse pulmonary smooth muscle cells (SMC). Primary cultures of mouse lung SMC from WT or Prkg1
-/-mice were isolated as described 26 . Briefly, a 21G needle was inserted into the right ventricle to perfuse the pulmonary circulation with hot HBSS (50 o C) and then with 2 µm irons in 0.5% agarose. The lung was then dissected, minced and collected in 15 ml tube. Following incubation with collagenase A (1mg/ml in HBSS, Roche Applied Sciences)
at 37 o C for 45 min with shaking, the rosetted cells were isolated and washed using a magnetic particle concentrator (Dynal MPC-15; Dynal Oslo, Norway). The freshly dispersed SMC were plated onto a 60 mm cell culture dish and incubated with Dulbecco's Modified Eagle medium (DMEM) containing 10% newborn calf serum, penicillin (100 units/ml) and streptomycin (100 μg/ml) in a humidified atmosphere of 5% CO2 in air at 37 o C and grown to 90-95% confluence.
These primary SMCs were used at passage 2 for all experiments.
Hemodynamic measurements. RVSP was determined with a 1.4F pressure transducer catheter (Millar Instruments) and AcqKnowledge software (Biopac Systems Inc.) as described previously 26 . Briefly, the 1.4F pressure transducer was inserted through the right external jugular vein of anesthetized mice (100 mg ketamine/5 mg xylazine/kg BW, i.p.) and threaded into the right ventricle. RVSP was then recorded and analyzed with AcqKnowledge software. To inhibit Rho kinase, Fasudil (60 mM in 25 µl saline) was administered into each mouse through tracheal instillation. RVSP was monitored continuously for 30 min following administration of Fasudil.
Carotid artery pressure was also determined with a 1.4F pressure transducer catheter. Western blotting. Western blot analysis was performed using the following antibodies: anti-Rho A phosphor-Ser188(1:500, Santa
. After paraffin processing, the tissues were cut into semi-thin 4 to 5 µm thick. For immunofluorescent staining, antigen retrieval was performed by incubating the slides in 10 mM sodium citrate (pH 6.0) at 95°C for 10 min. After 1h incubation at room temperature in a blocking solution containing 2% bovine albumin serum, 0.1% Triton X-100, and 2% normal goat serum, the sections were incubated for 2h at room temperature with anti-α smooth muscle actin mAb (1:400, Sigma-Aldrich). Nuclei were countstained with DAPI.
The anti-α smooth muscle actin-positive pulmonary arterial vessels per field (200X) were counted based on the diameter (<40µm versus >40µm). Twenty fields per section were randomly identified and counted.
RhoGTPase activity assay. The GTP-bound active forms of Rho A were determined by pulldown assay Cruz), anti-PKG-1 (1:1000, Stressgen Bioreagents), anti-VASP
(1:1000, Axxora), and anti-VASP phosphor-Ser239 (1:200, Axxora). Anti-β-actin (1:4000, BD Biosciences) were used as loading controls. Signals from immunoreactive bands were visualized by fluorography using an ECL reagent (Pierce). The intensity of each band was quantified using the NIH IMAGE J program. 28 . Cells were washed with ice-cold PBS five times and lysed in a lysis buffer (50 mmol/L Tris, pH 7.4, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 500 mmol/L NaCl, 10 mmol/L MgCl 2 , 10 µg/ml each of aprotinin and leupeptin, and 1 mmol/L phenylmethylsulfonyl fluoride). Similarly, lung tissues were homogenized with the same lysis buffer. After centrifugation at 18,000 x g at 4°C for 2 min, the extracts were incubated at 4°C for 60 min with glutathione-Sepharose beads coupled with glutathione-S-transferase (GST)-rhotekin fusion protein for determination of Rho A activity following manufacture's instruction (Cytoskeleton Inc). Bound Rho A proteins were quantified by Western blotting as described above. Total Rho A levels were also determined by direct Western blotting.
Statistical analysis Differences between groups were examined for statistical significance using Student's t-test. a P value less than 0.05 was considered significant. 
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To determine whether left heart dysfunction is involved in the pathogenesis of PH in Prkg1 mice is independent of left heart disease and systemic hypertension -/-mice, echocardiography in anesthetized mice was performed to evaluate in vivo cardiac function of age-matched littermates. As shown in Figure 4 and Previous pharmacological studies have demonstrated that PKG phosphorylates Rho A at Ser 188 and subsequently inhibits its membrane association which prevents activation of its downstream targets such as Rho kinase 13, 29, 30 . To assess whether PKG-I deficiency results in decreased phosphorylation of Rho A, we performed Western blotting on lung tissues from WT or
Prkg1
-/-mice using antibody against phospho-Ser 188 of Rho A. As shown in Figure 5A and 5B, a marked decrease of phosphorylation of RhoA Ser188 in Prkg1 -/-lungs was observed compared in WT lungs. To determine whether PKG-I deficiency promotes Rho A membrane association and activation, we performed a pull-down assay with glutathione-Sepharose beads coupled with glutathione-S-transferase (GST)-rhotekin fusion protein 28 . As shown in Figure 5C and 5D, there was a more than 2-fold increase in GTP bound Rho A in Prkg1 -/-lungs compared in WT lungs, whereas total Rho A expression was similar in both WT and Prkg1 -/-lungs, indicating Rho A activation in Prkg1 -/-lungs. Rho A activation was also markedly increased in SMC isolated from
-/-lungs compared with WT SMC (Figure 6 ).
PKG-I deficiency-induced vasoconstriction through activation of Rho A-Rho kinase signaling is a critical component of the pathogenesis of PH
We next addressed the mechanistic role of PKG-I deficiency-induced activation of Rho A-Rho kinase signaling in the pathogenesis of PH. Following measurement of RVSP at basal, the mice were acutely treated with Fasudil, a Rho kinase inhibitor, and RVSP was continuously monitored for additional 30 min. As shown in Figure 7 , there was a marked increase of RVSP in The biological importance of NO/cGMP/PKG signaling was first appreciated for promoting vascular smooth muscle relaxation mice. 31, 32 . NO stimulates cGMP synthesis and activates PKG in vascular SMC and thereby relaxes small arteries and arterioles resulting in a decreased blood pressure 33 . It has been shown that Prkg1 -/-mice exhibit defective relaxation of vascular, visceral, and penile smooth muscle [17] [18] [19] [20] , and thus Prkg1 -/-mice show impaired cGMP-dependent relaxation of large and small arteries and develop systemic hypertension as early as 4 weeks old 17 . However, the elevated blood pressure in Prkg1 -/-mice is returned to normal level at older age (e.g. 6 weeks old) 17, 34 . It has been proposed that the normalization of blood pressure in older
Prkg1
-/-mice is likely due to cross-activation of PKA by the high cGMP levels that are potentially generated in these mice 35, 36 . Here we show that Prkg1 -/-mice exhibit hypertensive pulmonary phenotypes at age of 6-8 weeks old independent of systemic hypertension and LV dysfunction. The persistent hypertensive pulmonary phenotypes suggest that vasorelaxation via the cGMP/PKG-I pathway is essential to the regulation of basal pulmonary vascular pressure which is in contrast to its role in regulation of basal blood pressure 17, 34 . Our recent studies have also shown that tyrosine nitration-mediated impairment of PKG-I activity secondary to loss of 24 , which is the characteristic feature of pulmonary vascular remodeling.
We have observed a more than 10-fold increase of muscularization of distal pulmonary vessels, and a drastic loss of microvascular perfusion, and widespread pre-capillary occlusion in Prkg1 14, [40] [41] [42] . PKG-I phosphorylates Rho A at Serine 188 and inhibits its membrane association and thereby prevents Rho kinase activation 13, 15 . Consistently, we observed decreased phosphorylation of . Inhaled Y-27362 or Fasudil causes sustained and selective pulmonary vasodilation in monocrotaline-induced PH and in spontaneous PH in fawn-hooded rats, as well as in chronically hypoxic rats 48 . Rho kinase is one of the main downstream effectors of Rho A. Upon activation, Rho A activates Rho kinase which phosphorylates the myosin phosphatase target subunit 1of smooth muscle myosin phosphatase at Thr-696 and leads to inhibition of its activity, an increased sensitivity of myosin light chain to calcium, and contraction 15, 49 . These data collectively suggest that activation of Rho A/Rho kinase signaling pathway secondary to decreased PKG activity is a critical component of the underlying mechanisms of PH in Prkg1 -/-mice. 
